Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Replimune Inc.
Fusion Pharmaceuticals Inc.
OncoNano Medicine, Inc.
Turnstone Biologics, Corp.
National Cancer Institute (NCI)
Provectus Pharmaceuticals
Incyte Corporation
National Institutes of Health Clinical Center (CC)